Review of pulmonary adverse effects of infliximab therapy in Crohn’s disease-Reference-Cited by-同舟云学术

Review of pulmonary adverse effects of infliximab therapy in Crohn’s disease

Published:2016-03-16 Issue:6 Volume:15 Page:769-775
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Patel Dhiren¹,Madani Shailender¹,Patel Shraddha²,Guglani Lokesh³

Affiliation:

1. Pediatric Gastroenterology, The Carman and Ann Adams Department of Pediatrics, Children’s Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA

2. Department of Emergency Medicine, Wayne State University, Detroit, MI, USA

3. Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep Medicine (PACS) Division, Department of Pediatrics, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA

Publisher

Informa Healthcare

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/14740338.2016.1160053

Reference55 articles.

1. Food and Drug Administration. FDA approves remicade for children with Crohn’s disease. P06-71, 2006.

2. Current therapy of pediatric Crohn’s disease

3. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease

4. Cardiopulmonary Arrest After Severe Anaphylactic Reaction to Second Infusion of Infliximab in a Patient with Ankylosing Spondylitis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies;CHEST Pulmonary;2023-12

2. Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance;International Journal of Molecular Sciences;2023-02-04

3. Cavitary lung nodules as an extraintestinal manifestation of ulcerative colitis;BMJ Case Reports;2022-09

4. 3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium–Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome;Frontiers in Pharmacology;2022-06-15

5. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor;Frontiers in Immunology;2021-12-20